当前位置： SCI文献检索 > VACCINE期刊下所有文献 > Protective and antifecundity effects of Sm-p80-based DNA vaccine formulation against Schistosoma mansoni in a nonhuman primate model.

Protective and antifecundity effects of Sm-p80-based DNA vaccine formulation against Schistosoma mansoni in a nonhuman primate model.

Abstract：

:Schistosomiasis is an important parasitic disease for which there is no available vaccine. We have focused on a functionally important antigen of Schistosoma mansoni, Sm-p80, as a vaccine candidate because of its consistent immunogenicity, protective potential and antifecundity effect observed in murine models; and for its pivotal role in the immune evasion process. In the present study we report that an Sm-p80-based DNA vaccine formulation confers 38% reduction in worm burden in a nonhuman primate model, the baboon (Papio anubis). Animals immunized with Sm-p80-pcDNA3 exhibited a decrease in egg production by 32%. Sm-p80 DNA elicited specific immune responses that include IgG; its subtypes IgG1 and IgG2; and IgM in vaccinated animals. Peripheral blood mononuclear cells (PBMCs) from immunized animals when stimulated in vitro with Sm-p80 produced appreciably more Th1 response enhancing cytokines (IL-2, IFN-gamma) than Th2 response enhancing cytokines (IL-4, IL-10). PBMCs produced appreciably more spot-forming units for INF-gamma than for IL-4 in enzyme-linked immunosorbent spot (ELISPOT) assays. Overall it appears that even though a mixed (Th1/Th2) type of humoral antibody response was generated following immunization with Sm-p80; the dominant protective immune response is Th1 type. These data reinforce the potential of Sm-p80 as an excellent vaccine candidate for schistosomiasis.

journal_name

Vaccine

journal_title

Vaccine

authors

Ahmad G,Zhang W,Torben W,Damian RT,Wolf RF,White GL,Chavez-Suarez M,Kennedy RC,Siddiqui AA

doi

10.1016/j.vaccine.2009.02.096

subject

Has Abstract

pub_date

2009-05-11 00:00:00

pages

2830-7

issue

21

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(09)00368-5

journal_volume

27

pub_type

杂志文章

相关文献

VACCINE文献大全
  • Recombinant vaccine against hepatitis E: dose response and protection against heterologous challenge.

    abstract：:Thirty-two rhesus monkeys were used to evaluate the dose response of a recombinant HEV vaccine, and the efficacy of the vaccine based on the ORF2 protein of the Pakistani strain for pre- and post-exposure vaccination against intravenous challenge with homologous or heterologous virus was examined. Post-exposure vaccin...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(97)00145-x

    authors： Tsarev SA,Tsareva TS,Emerson SU,Govindarajan S,Shapiro M,Gerin JL,Purcell RH

    更新日期：1997-12-01 00:00:00

  • Genetic polymorphisms in host antiviral genes: associations with humoral and cellular immunity to measles vaccine.

    abstract：:Host antiviral genes are important regulators of antiviral immunity and plausible genetic determinants of immune response heterogeneity after vaccination. We genotyped and analyzed 307 common candidate tagSNPs from 12 antiviral genes in a cohort of 745 schoolchildren immunized with two doses of measles-mumps-rubella (...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.09.043

    authors： Haralambieva IH,Ovsyannikova IG,Umlauf BJ,Vierkant RA,Shane Pankratz V,Jacobson RM,Poland GA

    更新日期：2011-11-08 00:00:00

  • Can the vaccine adverse event reporting system be used to increase vaccine acceptance and trust?

    abstract：:Vaccine refusal has an impact on public health, and the human pappillomavirus (HPV) vaccine is particularly underutilized. Research suggests that it may be difficult to change vaccine-related attitudes, and there is currently no good evidence to recommend any particular intervention strategy. One reason for vaccine he...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2016.03.087

    authors： Scherer LD,Shaffer VA,Patel N,Zikmund-Fisher BJ

    更新日期：2016-05-05 00:00:00

  • Systems vaccinology: Enabling rational vaccine design with systems biological approaches.

    abstract：:Vaccines have drastically reduced the mortality and morbidity of many diseases. However, vaccines have historically been developed empirically, and recent development of vaccines against current pandemics such as HIV and malaria has been met with difficulty. The advent of high-throughput technologies, coupled with sys...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2015.03.072

    authors： Hagan T,Nakaya HI,Subramaniam S,Pulendran B

    更新日期：2015-09-29 00:00:00

  • Mucosal immunization with a replication-deficient adenovirus vector expressing murine cytomegalovirus glycoprotein B induces mucosal and systemic immunity.

    abstract：:The murine cytomegalovirus (MCMV) glycoprotein B (gB) gene was expressed in an adenovirus replication-deficient vector. This virus, designated Ad-gB, was used to immunize BALB/c and B6 mice by the intranasal (i.n.) route to induce an immune response. Following primary immunization, antibody was detected in serum of 10...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(03)00037-9

    authors： Shanley JD,Wu CA

    更新日期：2003-06-02 00:00:00

  • Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells.

    abstract：:Cytomegalovirus infections are an important cause of disease for which no licensed vaccine exists. Recent studies have focused on the gH/gL/UL128-131 complex as antibodies to gH/gL/UL128-131 neutralize viral entry into epithelial cells. Prior studies have used cells from the retinal pigment epithelium, while to preven...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.01.079

    authors： Saccoccio FM,Sauer AL,Cui X,Armstrong AE,Habib el-SE,Johnson DC,Ryckman BJ,Klingelhutz AJ,Adler SP,McVoy MA

    更新日期：2011-03-24 00:00:00

  • Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/human immunodeficiency virus (SHIV33).

    abstract：:HIV-1 Tat protein activates resting cells, rendering them permissive for viral replication. Replication of HIV-1 in vitro is enhanced by intercellular passage of Tat protein and inhibited by anti-Tat antibodies. Tat dependence of HIV-1 replication in vivo during acute, chronic asymptomatic and AIDS stages of infection...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(00)00085-2

    authors： Goldstein G,Manson K,Tribbick G,Smith R

    更新日期：2000-06-15 00:00:00

  • RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial.

    abstract：BACKGROUND:We report the first-in-concept human trial of the safety, tolerability and immunogenicity when a novel TLR 7/8/RIG I agonist RNA-based adjuvant, CV8102, was administered alone or mixed with fractional doses of a licensed rabies vaccine (Rabipur®) as model antigen. METHODS:The primary objective was to assess...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2019.02.024

    authors： Doener F,Hong HS,Meyer I,Tadjalli-Mehr K,Daehling A,Heidenreich R,Koch SD,Fotin-Mleczek M,Gnad-Vogt U

    更新日期：2019-03-22 00:00:00

  • Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes.

    abstract：:Genetically modified bacterial flagellin (Fla), a Toll-like receptor-5 (TLR5) ligand, was evaluated as a fusion partner for human papillomavirus (HPV) L2-based immunogens in two animal challenge models; either cutaneous inoculation of rabbits with HPV 'quasivirions' containing cottontail rabbit papillomavirus (CRPV) g...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2014.04.032

    authors： Kalnin K,Tibbitts T,Yan Y,Stegalkina S,Shen L,Costa V,Sabharwal R,Anderson SF,Day PM,Christensen N,Schiller JT,Jagu S,Roden RB,Almond J,Kleanthous H

    更新日期：2014-06-12 00:00:00

  • Combined vaccination against yellow fever and typhoid fever: a comparative trial.

    abstract：:In order to evaluate a combination of yellow fever and typhoid fever vaccine, we conducted a controlled trial comparing reactogenicity and immunogenicity of Vi polysaccharide (ViPS) vaccine and yellow fever 17D (YF) vaccine after single, simultaneous and combined administration. The combined YF/ViPS vaccine was prepar...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1016/0264-410x(94)90267-4

    authors： Ambrosch F,Fritzell B,Gregor J,Jonas S,Kollaritsch H,Teulieres L,Wiedermann G

    更新日期：1994-05-01 00:00:00

  • Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose.

    abstract：:Longitudinal serum samples were collected from 542 children that had participated in a Swedish pertussis vaccine trial 1992-1995 [Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Me...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2005.06.009

    authors： Hallander HO,Gustafsson L,Ljungman M,Storsaeter J

    更新日期：2005-11-16 00:00:00

  • Nef modulates the immunogenicity of Gag encoded in a non-infectious HIV DNA vaccine.

    abstract：:Gag-CD8+ T cell responses are associated with immune control of HIV infection. Since during HIV infection Nef impairs T cell responses, we evaluated whether deletion of nef from a non-infectious HIV DNA vaccine (Delta4 Nef+), creating Delta5 Nef(-), would affect its immunogenicity. When compared with Delta4, mice inje...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2008.05.057

    authors： Arrode G,Hegde R,Jin Y,Singh DK,Narayan O,Chebloune Y

    更新日期：2008-07-23 00:00:00

  • Long-term impact of pneumococcal polysaccharide vaccination on nasopharyngeal carriage in children previously vaccinated with various pneumococcal conjugate vaccine regimes.

    abstract：:Previously, the Fiji Pneumococcal Project (FiPP) evaluated reduced dose immunization schedules that incorporated pneumococcal protein conjugate and/or polysaccharide vaccine (PCV7 and 23vPPV, respectively). Immune hyporesponsiveness was observed in children vaccinated with 23vPPV at 12 months of age compared with chil...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2015.07.059

    authors： Boelsen LK,Dunne EM,Lamb KE,Bright K,Cheung YB,Tikoduadua L,Russell FM,Mulholland EK,Licciardi PV,Satzke C

    更新日期：2015-10-13 00:00:00

  • DNA vaccination with the Mycobacterium marinum MMAR_4110 antigen inhibits reactivation of a latent mycobacterial infection in the adult Zebrafish.

    abstract：BACKGROUND:Tuberculosis is a major challenge for health care, as options for its treatment and prevention are limited. Therefore, novel approaches, such as DNA vaccination, to both prevent primary infections and the reactivation of latent infections need to be developed. A Mycobacterium marinum infection in adult zebra...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2020.06.053

    authors： Niskanen M,Myllymäki H,Rämet M

    更新日期：2020-07-31 00:00:00

  • Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R).

    abstract：:Human papilloma virus (HPV) found in 99.7% of cervical cancers represents an attractive immunotherapeutic target for novel adjuvant dendritic cell (DC) immunotherapy. DC primed with HPV antigens have been shown to be capable of inducing CTL responses powerful enough to eradicate established murine tumours expressing H...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/s0264-410x(02)00599-6

    authors： Adams M,Navabi H,Jasani B,Man S,Fiander A,Evans AS,Donninger C,Mason M

    更新日期：2003-01-30 00:00:00

  • Epidemiology of varicella in Haidian district, Beijing, China-2007-2015.

    abstract：BACKGROUND:1-Dose varicella vaccination was recommended for children in Beijing before November 2012. To further control school-based outbreaks and decrease incidence, a 2-dose vaccination was implemented in 2013. We described the varicella epidemiology and assessed impact of the 2-dose vaccination in Haidian district,...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2017.03.044

    authors： Fu J,Jiang C,Wang J,Zhao F,Ma T,Shi R,Zhao Y,Zhang X

    更新日期：2017-04-25 00:00:00

  • Phase II randomized, placebo-controlled trial of M. vaccae-derived protein (PVAC) for the treatment of psoriasis.

    abstract：:The treatment effect against psoriasis of an antigen (delipidated, deglycolipidated form of M. vaccae-PVAC) was investigated. One hundred and sixty-five patients were enrolled in three arms (50 or 15 microg or placebo), each receiving a total of two intradermal injections (days 0 and 21). At week 12, a 75% decrease in...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2006.03.047

    authors： Netto EM,Takahashi D,de Fátima Paim de Oliveira M,Barbosa P,Ferraz N,Paixão A,Oyafuso LK,Bortoletto C,Matos D,Paixão M,da Silva AO,Badaro R

    更新日期：2006-06-05 00:00:00

  • Like mother, like daughter? Mother's history of cervical cancer screening and daughter's Human Papillomavirus vaccine uptake in Flanders (Belgium).

    abstract：OBJECTIVE:We investigated whether and to what extent the uptake of the Human Papillomavirus (HPV) vaccine by girls aged 12-18 was related to the cervical cancer screening history of age-appropriate older female household members (assumed to be their mothers) in Flanders (Belgium). METHODS:We studied administrative rec...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.08.039

    authors： Lefevere E,Hens N,Theeten H,Van den Bosch K,Beutels P,De Smet F,Van Damme P

    更新日期：2011-10-26 00:00:00

  • A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors.

    abstract：:Persistent infection by high risk genotypes of human papillomavirus (HPV) is the cause of cervical cancer, which remains one of the most common cancers among women worldwide. In addition, there is a growing appreciation that high risk HPVs are associated with a number of other cancers including anogenital cancers as w...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.07.090

    authors： Wick DA,Webb JR

    更新日期：2011-10-13 00:00:00

  • Beliefs around childhood vaccines in the United States: A systematic review.

    abstract：BACKGROUND:While childhood vaccines are safe and effective, some parents remain hesitant to vaccinate their children, which has led to outbreaks of vaccine preventable diseases. The goal of this systematic review was to identify and summarize the range of beliefs around childhood vaccines elicited using open-ended ques...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2019.08.068

    authors： Gidengil C,Chen C,Parker AM,Nowak S,Matthews L

    更新日期：2019-10-23 00:00:00

  • Determinants of under-immunization and cumulative time spent under-immunized in a Quebec cohort.

    abstract：BACKGROUND:Under-immunization refers to a state of sub-optimal protection against vaccine preventable diseases. Vaccine coverage for age may not capture intentional or non-intentional spacing of vaccines in the recommended provincial immunization guidelines. We aimed to identify factors associated with coverage and und...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2017.08.072

    authors： O'Donnell S,Dubé E,Tapiero B,Gagneur A,Doll MK,Quach C

    更新日期：2017-10-13 00:00:00

  • TLR7/8 agonists activate a mild immune response in rabbits through TLR8 but not TLR7.

    abstract：:Toll-like receptors 7 (TLR7) and 8 (TLR8) recognize viral single-stranded RNA and small molecular weight agonists to activate anti-viral immune responses. TLR8s from different species have distinct ligand recognitions. For example, human TLR8 is responsive to ligand stimulation, but mouse and rat TLR8 are activated by...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2014.07.104

    authors： Lai CY,Liu YL,Yu GY,Maa MC,Leu TH,Xu C,Luo Y,Xiang R,Chuang TH

    更新日期：2014-09-29 00:00:00

  • Induction of T-cell response by a DNA vaccine encoding a novel HLA-A*0201 severe acute respiratory syndrome coronavirus epitope.

    abstract：:The severe acute respiratory syndrome coronavirus nucleocapsid protein (SARS-CoV N) is one of the major targets for SARS vaccine due to its high potency in triggering immune responses. In this study, we have identified a novel HLA-A*0201 restricted epitope, N220 (LALLLLDRL), of the SARS-CoV N-protein through bioinform...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2007.05.025

    authors： Cheung YK,Cheng SC,Sin FW,Chan KT,Xie Y

    更新日期：2007-08-10 00:00:00

  • Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen.

    abstract：:We employed DNA shuffling and screening technologies to develop a single recombinant dengue envelope (E) antigen capable of inducing neutralizing antibodies against all four antigenically distinct dengue serotypes. By DNA shuffling of codon-optimized dengue 1-4 E genes, we created a panel of novel chimeric clones expr...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2005.07.100

    authors： Apt D,Raviprakash K,Brinkman A,Semyonov A,Yang S,Skinner C,Diehl L,Lyons R,Porter K,Punnonen J

    更新日期：2006-01-16 00:00:00

  • Antibodies against Haemophilus influenzae type b in The Gambia: investigating the extent of protection across age groups.

    abstract：:Following a landmark clinical trial, the vaccine against Haemophilus influenzae type b (Hib) was introduced in The Gambia in 1997. Whilst the immunogenicity of this vaccine is well established subsequent to the doses administered under the EPI schedule, little data exists assessing longevity of protection, using serol...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2014.06.078

    authors： Idoko OT,Roberts E,Cox M,Jafali J,Njie-Jobe J,Mackenzie G,Ota MO,Kampmann B

    更新日期：2014-08-06 00:00:00

  • A combination vaccine confers full protection against co-infections with influenza, herpes simplex and respiratory syncytial viruses.

    abstract：:Combined/composite vaccines should be useful in reducing the number of vaccinations and provide more flexibility in confronting biological warfare scenarios. We tested the effectiveness of a composite genetic vaccine designed from previously known protective antigens directed against influenza A virus (INF-A), herpes ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(01)00352-8

    authors： Talaat AM,Lyons R,Johnston SA

    更新日期：2001-11-12 00:00:00

  • Economic benefits for the family of inactivated subunit virosomal influenza vaccination of healthy children aged 3-14 years during the annual health examination in private paediatric offices.

    abstract：:Taking the results of a prospective cohort study by our group that evaluated the effectiveness of the inactivated subunit virosomal influenza vaccine (Inflexal V), Crucell-Berna) in the prevention of influenza-related diseases and the reduction of its negative economic consequences, the economic costs and benefits for...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2009.01.053

    authors： Salleras L,Navas E,Domínguez A,Ibáñez D,Prat A,Garrido P,Asenjo MA,Torner N

    更新日期：2009-05-26 00:00:00

  • Characterization of the immune response to DNA vaccination strategies for schistosomiasis candidate antigen, Sm-p80 in the baboon.

    abstract：:Even though schistosomicidal agents and other control measures, including public hygiene and snail control exist, development of an efficacious vaccine still remains the most potentially powerful method for control of schistosomiasis. In our continuing efforts to develop a vaccine against schistosomiasis, we have sele...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2004.09.018

    authors： Siddiqui AA,Pinkston JR,Quinlin ML,Saeed Q,White GL,Shearer MH,Kennedy RC

    更新日期：2005-02-10 00:00:00

  • Scale-up for bulk production of vaccine against meningococcal disease.

    abstract：:At the Netherlands Vaccine Institute (NVI) a vaccine against Neisseria meningitidis serogroup B organisms based on different porA subtypes contained in outer membrane vesicles (OMVs) is in advanced stage of development and will be evaluated in clinical trial studies in the near future. In order to meet the expected de...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2007.06.008

    authors： Baart GJ,de Jong G,Philippi M,van't Riet K,van der Pol LA,Beuvery EC,Tramper J,Martens DE

    更新日期：2007-08-21 00:00:00

  • Designing and engineering of DNA-vaccine construction encoding multiple CTL-epitopes of major HIV-1 antigens.

    abstract：:A synthetic T cell immunogen (TCI) has been designed as a candidate DNA-based vaccine against Human immunodeficiency virus (HIV)-1 using cytotoxic T lymphocytes (CD8(+) CTL) and T-helper lymphocytes (CD4(+) Th) epitopes retrieved from the Los Alamos HIV Molecular Immunology Database. The protein 392 amino acids in len...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2003.09.048

    authors： Bazhan SI,Belavin PA,Seregin SV,Danilyuk NK,Babkina IN,Karpenko LI,Nekrasova NA,Lebedev LR,Ignatyev GM,Agafonov AP,Poryvaeva VA,Aborneva IV,Ilyichev AA

    更新日期：2004-04-16 00:00:00